skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Greetings team 5i,

Beside my core portfolio, I invest about 5% of my money in a “fun” portfolio. It has not been much fun recently. I bought ABBV (at the top) in order to write covered calls and cash-secured uncovered puts.

These calls, written just out-of-the-money and puts written just in-the-money on Mondays with the expiry date on the Friday of the same week, have produced premiums ranging from $US0.81 to $US2.73 which happened this week.

Why is there such a wide range of premium prices and what do the higher premiums suggest?

Thank you.

Milan
Read Answer Asked by Milan on October 30, 2018
Q: I have been investing in the market for 45 years now, many wonderful gains and some 100% loses, example Worldcom(fraud), ask Bernie to confirm. From all my major loses i try to learn something that will help me in the future. I was surprised that you bought into the stock when it was already up a lot and was really pumped by a couple of guests on BNN. My concern with this company was that it was doing nothing new and was competing with major health companies in the US that had market caps in the billions. If this was not some new major new mousetrap, the headwinds for this tiny company were just too risky. Did 5i get caught up in this hype on BNN and the canadian market rise so fast, and in the end, what did 5i learn from this type of investing in the future?
Read Answer Asked by eugene on October 30, 2018
Q: Hi could you please explain why you think healthcare may be a good place to hide if markets stay week? And does this include biotech without revenue or are you referring top the larger drug companies with stable revenue?
Read Answer Asked by Kel on October 29, 2018
Q: ABBV share price has slumped from approx. $95 to $82.50 in the past 5 days. Marinol was recently approved by the FDA. ABBV currently has a Forward P/E ratio of 10.72. I understand that the industry's average Forward P/E is 15.85.

What is your view of this stock. Seems like it might be an opportune time to buy and play the marijuana angle from a safe distance.

The Webinar yesterday was great. I hope there are more. Thank you for your services.
Read Answer Asked by Grant on October 26, 2018
Q: Hello. Can you point me in the direction of a few solid health sector, dividend paying stock options that would be suitable to hold within an RRSP? I’m looking at a five to eight year horizon and consider myself as a ‘low to moderate’ risk investor.
PS found recent ‘ How to Pick a Stock in 2018’ very helpful. Thanks!
Read Answer Asked by Heather on October 25, 2018
Q: In your reply to my previous question you mentioned you thought Reliq Management had misrepresented revenue. My understanding was that the items to be restated comprise part or all of the Accounts Receivable as reported end of March. Is it considered misrepresentation when A/R turn out to not be collectible do to an unexpected non-reimbursement? It doesn't seem as bad or the same as when Nortel was misrepresenting, booking sales in Texas that had not actually occurred. Any detail you can provide on how analysts view these kind of snafus is appreciated.
Read Answer Asked by John on October 19, 2018
Q: I still like Celgene, but I'm considering harvesting a tax loss on it. What pharma stocks would you recommend I replace it with? Or would you wait the 30 days and hope to buy CELG back at a similar level again? I think every ounce of bad news is baked into it and so it might have some big upside if things like the patent fight on Revlimid work out in CELG's favor.
Read Answer Asked by Alex on October 19, 2018
Q: Just as a follow up to my previous question and a comment I am sure is on many members mind. I see that RHT is up a bit today after the call. Maybe a dead cat bounce who knows. The dilemma in selling at a 75% loss is that I do not get the tax loss as its in my TFSA. I imagine many members are in the same predicament. What little is left in the security, will make such a small difference in the overall portfolio, I would rather hang on and hope that your first impression of the Company was correct. Not sure my mentality is appropriate here, but I would rather take the lesson and hold, than to sell and then see it go back up.

Thoughts?

KC
Read Answer Asked by Kelly on October 18, 2018
Q: With all the talk of an admittedly bad mistake (at best) by management, what has happened to the technology? Didn't you believe in iUgo and the accompanying smart phone app and the jump this company supposedly had in producing a superior remote monitoring product for chronic care patients? But they bruise their heals because they didn't understand CMS billing well enough and, oh well, so much for that technology? Is it great technology or not? Will it save government health care money or not? If it will, then surely CMS will come around and recognize this and eventually reimburse for the service, no? This all just seems odd that one day you're touting this company as having the one of the best technology stories in the health technology space, and the next they are a dog because they made a mistake. Is there no room for growing pains for a start up?
Read Answer Asked by John on October 18, 2018
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!